home.social

#repo4eu β€” Public Fediverse posts

Live and recent posts from across the Fediverse tagged #repo4eu, aggregated by home.social.

  1. πŸ”πŸ“„ 'Prioritizing repurposable drugs for Alzheimer's disease using network-based analysis with concurrent assessment of Long QT syndrome risk.' - a #DrugRepurposing Research article on #ScienceOpen:

    ➑️ scienceopen.com/document?vid=c

    #REPO4EU #NetworkMedicine #AlzheimersResearch #QTInterval #Interactome #Bioinformatics

  2. πŸ”πŸ“„ 'Prioritizing repurposable drugs for Alzheimer's disease using network-based analysis with concurrent assessment of Long QT syndrome risk.' - a #DrugRepurposing Research article on #ScienceOpen:

    ➑️ scienceopen.com/document?vid=c

    #REPO4EU #NetworkMedicine #AlzheimersResearch #QTInterval #Interactome #Bioinformatics

  3. πŸ”πŸ“„ 'Prioritizing repurposable drugs for Alzheimer's disease using network-based analysis with concurrent assessment of Long QT syndrome risk.' - a #DrugRepurposing Research article on #ScienceOpen:

    ➑️ scienceopen.com/document?vid=c

    #REPO4EU #NetworkMedicine #AlzheimersResearch #QTInterval #Interactome #Bioinformatics

  4. πŸŒπŸ” Advancing #DrugRepurposing for #PrecisionMedicine in Europe and beyond β€” explore Drug Repurposing Central via #ScienceOpen and browse over 10,000 publications in the Drug Repurposing Research Collection. #REPO4EU πŸ§¬πŸ’Šβ€΅οΈ

    drugrepocentral.scienceopen.co

  5. πŸŒπŸ” Advancing #DrugRepurposing for #PrecisionMedicine in Europe and beyond β€” explore Drug Repurposing Central via #ScienceOpen and browse over 10,000 publications in the Drug Repurposing Research Collection. #REPO4EU πŸ§¬πŸ’Šβ€΅οΈ

    drugrepocentral.scienceopen.co

  6. Just finished the final review with the EU Commission's #HADEA Project Officer and experts for our concluded #H2020 #drugrepurposing project, REPO-TRIAL (repo-trial.eu/). We have already made a smooth transition to the much larger #HorizonEurope follow-up project, #REPO4EU (repo4.eu/) which is building a a drug repurposing platform. Stay tuned!